Abstract:OBJECTIVE Rett syndrome (RTT) is a neurodevelopmental disorder which causes severe mental retardation. This study aimed at elucidating clinical features of 66 Chinese RTT cases diagnosed by The Department of Pediatric Neurology, Peking University First Hospital since 1987, and at analysis of the MeCP2 genotype / phenotype correlation. METHODS Sixty-six RTT cases were followed up every one to two years to get the information of their clinical manifestations and the response to the L-carnitine treatment which was administered to the patients at a dose of 80-100 mg/(kg d). MeCP2 mutation analysis by PCR and sequencing were performed on 39 cases. RESULTS In this cohort of cases, the onset of the disease occurred between 3 and 38 months of age, 89% of the cases lost their purposeful hand use at 7 months to six years of age, all the cases had stereotype hand movement which presented at 1 to 5 years of age, 85% of the cases lost language ability at 11 months to eight years of age, 21% of the cases lost the ability of walking at ages of 2 years and 9 months to 15 years. The symptoms/signs such as small head circumference, seizures, breathing irregularities, teeth grinding, scoliosis/ kyphosis were presented in many of the cases. The clinical manifestations were improved in 6 cases after L-carnitine treatment. MeCP2 gene mutation was found in 64% of the cases. Two cases with non-sense mutation C502t (amino acid change R168X) died, two cases with missense mutation C397T (amino acid change R133C) and one case with missense mutation A398T (amino acid change R133H) preserved several words. CONCLUSION Deceleration of the head growth, loss of acquired purposeful hand use, stereotype hand movement and language deterioration were the main characteristics of RTT. L-carnitine could improve the clinical manifestation of some cases. There are some correlations between MeCP2 genotype and phenotype.

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Research Progress of Rett Syndrome Causing Gene MECP2-The Structure, Function and Modulation of MECP2

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

The molecular pathology of rett syndrome

MECP2 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials

Rett Syndrome-Causing Mutations Compromise MeCP2-mediated Liquid–liquid Phase Separation of Chromatin

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

MECP2 Mutation Spectrum and Its Clinical Characteristics in a Chinese Cohort

X Chromosome Inactivation in Rett Syndrome and Its Correlations with MECP2 Mutations and Phenotype.

MECP2 and CDKL5 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Clinical Feature of Rett Syndrome and MeCP2 Genotype/phenotype Correlation Analysis

Genome-Wide Analysis Reveals Methyl-Cpg-Binding Protein 2-Dependent Regulation Of Micrornas In A Mouse Model Of Rett Syndrome

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

Dysregulated Cortical Synaptic Plasticity under Methyl-Cpg Binding Protein 2 Deficiency and Its Implication in Motor Impairments

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

Molecular Mechanisms of Rett Syndrome: Emphasizing the Roles of Monoamine, Immunity, and Mitochondrial Dysfunction

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain